Rare FTD Cases Another Example of Lysosomal Pathology in Dementia
Mutations in CHMP2B gene have been linked to mysterious lysosomal inclusions.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
Paper Alert: Promising Phase 2 Results for Agitation Drug Published
Avanir Pharmaceuticals’ AVP-923 calmed Alzheimer’s patients in a small 10-week study.
Catalog of Humanity—Variation in 2,500 Genomes Ready for Perusal
The 1000 Genomes consortium released its final report and sequence data set. It will help scientists studying neurodegenerative diseases better interpret GWAS findings.
Avagacestat Demise Has Silver Lining for CSF Biomarkers
Analysis of the avagacestat trial of 2012 details the side effects that sank the drug, and the outcomes that support CSF biomarkers for prodromal Alzheimer’s disease.
Two-in-One: Single Protein Untangles and Chops Up Tau Fibrils
Researchers report the first known enzyme that combines disaggregase and protease activity.
Do Membraneless Organelles Host Fibril Nucleation?
Granules in the nucleus and cytoplasm may owe their genesis and shape to liquefied forms of ALS-linked proteins, such as FUS and hnRNPA1.
Neurons Derived Directly from Skin Cells Act the Age of Their Donors
When researchers directly convert skin cells into neurons, skipping the stem-cell step, the cells express gene signatures that reflect the age of their donors.
VasCog 2015—Highlights of a Conference
White-matter hyperintensities, astrocyte damage, hypoperfusion, and amyloid angiopathy draw scrutiny as factors in the complex relationship between cerebrovascular and neurodegenerative processes in dementia.
VasCog Conference 2015
VasCog 2015—Highlights of a Conference Every so often, an intrepid reader steps forward to enlighten the community by organizing notes from a conference that few fellow Alzforum readers got to attend. This week, Donna Wilcock of the University of Kentucky
Not Sexy but Oh-So-Important: Committee Blesses Way to Measure CSF Aβ
Moving toward a common standard for fluid-based Alzheimer’s diagnosis in routine clinical care, an intergovernmental metrology agency has certified a way of quantifying Aβ42.
Reinforcement, or Replacement? Stem Cell Strategies Divide to Conquer
Recent studies exemplify the burgeoning array of stem cell strategies to treat neurodegeneration, ranging from sending in supportive cells to switching out neurons.
Society for Neuroscience Annual Meeting 2015
Snapshots from the Society for Neuroscience Annual Meeting Microglia Control Synapse Number in Multiple Disease States Might Normalizing Brain Development Help in Down’s Syndrome? Potential Parkinson’s Treatments Target α-Synuclein, Cell Replacement Alzhe
C9ORF72 Mice Point to Gain of Toxic Function in ALS, FTD
Phenotypes vary depending on the partial or full-length nature of the C9ORF72 transgene.
FUS Phase Transitions: Liquids and Gels
The ALS- and FTD-linked protein condenses into liquid organelles but also tends to form hydrogels, some of which are permanent and toxic.
Snapshots from the Society for Neuroscience Annual Meeting
Basic science inspires conference goers in Chicago.
Current Filters
No filters selected